SynthesisFrontiers in immunology2025
Anti-β2 glycoprotein domain 1 antibody as a diagnostic marker for antiphospholipid syndrome and a predictor of thrombosis: a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The diagnostic and prognostic values of non-criteria antiphospholipid antibodies in obstetric antiphospholipid syndrome.BMC pregnancy and childbirth · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-β2 glycoprotein I domain 1 (anti-β2GPI-D1) antibodies have shown promise as diagnostic and prognostic markers for antiphospholipid syndrome (APS), but their clinical significance remains uncertain. This systematic review and meta-analysis evaluated the diagnostic accuracy of anti-β2GPI-D1 for APS and its association with thrombotic risk. A comprehensive search was conducted across PubMed, Web of Science, and Embase up to July 18, 2024. Eighteen studies (2,060 APS patients and 3,013 controls) were included in the diagnostic analysis, revealing a pooled sensitivity of 52% (95% CI 46%-58%) and specificity of 95% (95% CI 88%-98%). Anti-β2GPI-D1 demonstrated strong diagnostic value in distinguishing APS from other autoimmune diseases and healthy individuals, though its utility in differentiating APS from aPL carriers was limited. Additionally, five prospective cohort studies (210 APS patients, 430 aPL carriers, and 42 SLE patients) showed that anti-β2GPI-D1 was associated with an increased risk of thrombosis (pooled RR 1.75, 95% CI 1.07-2.87). Our findings suggest that anti-β2GPI-D1 offers high specificity and moderate sensitivity for APS diagnosis and may serve as a predictor of thrombosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.